» Thanks to @Dogster who found this new Aderans press release and
» posted it - IMHO a little bit too hidden - in another (related) topic …
»
I’ve often said that ARI would most likely need to extend phase II in order to figure out consistency. The good news is the number of patients they are treating is an extremely good sign.
I realize a lot of people have contempt for doctor Gho due to his not being able to figure out a consistent protocol in a timely manner, but it’s important to realize, he got there first, and much can be learned from observing the obstacles he encountered. The way he progressed is exactly the way other research firms will have to progress in order to figure this out.
- get excited about some patients who have an extremely good response to treatment.
- perform additional studies in an attempt to get more people to have a good response to treatment.
What this says is, ARI’s protocol is not currently marketable. They need to work on the consistency issue, but the initial results in some patients are extremely promising.
Gho’s been here before, as was ICX prior to running out of money. IMO, ARI has the best chance of solving this due to their very well chosen team, their multi-cell approach, and their neogenic approach. It’s important for the cells to be able to clump in 3-d in order to provide the best cell signaling environment. ARI’s matrix approach provides the best chance at developing a consistent technique, because it’s clumped environment depends on host signals the least of all methods attempted so far. Futhermore, the approach does not depend on the health of the remaining shrunken follicles, which can lead to a patchy consistency issue.
IMO, ARI is saying, this works, but we need to figure out how to present it as a consistent single protocol solution.
Years ago, I suggested that Gho provide a test to his HT patients in order to judge their response to treatment. This way, it minimizes the up front expense if the patient is a poor responder. However, Gho felt that, since the technique has patchy consistency on individual patients, the treatment can not be rolled out in that fashion. IMO, ARI’s matrix approach has a high chance of leading to a more even consistency in a single patient. This means, ARI could potentially roll out the product early, even if they can’t get it working well on 100% of patients. As their understanding progressed, they could increasingly treat a higher percentage of patients.
That being said, let’s hope they can figure out a single protocol, prior to the initial release, that works well on everybody.
